Sanofi’s protein-based Covid-19 vaccine, Nuvaxovid, has demonstrated a more favorable tolerability profile compared to Moderna’s mRNA-based Spikevax (formerly mNEXSPIKE) in recent head-to-head evaluations, according to data reviewed by global health authorities. The findings, which emerged from comparative safety monitoring in multiple countries, contribute to ongoing discussions about vaccine choice, particularly for populations sensitive to reactogenicity or with specific medical histories.
While both vaccines remain authorized and recommended for use in preventing severe Covid-19, real-world evidence suggests that Nuvaxovid may be associated with lower rates of systemic side effects such as fever, fatigue, and myalgia following administration. These observations are particularly relevant in booster campaigns and for individuals who experienced pronounced reactions after prior mRNA doses.
The comparison does not imply differences in efficacy; rather, it highlights variations in how the immune system responds to different vaccine platforms. Nuvaxovid, developed using recombinant nanoparticle technology with Matrix-M adjuvant, presents the SARS-CoV-2 spike protein in a structured format without using genetic material. In contrast, Spikevax delivers mRNA encoding the spike protein, prompting cells to produce the antigen internally.
This mechanistic distinction may underlie the differing tolerability patterns observed in post-authorization studies. Regulatory bodies including the European Medicines Agency (EMA) and the World Health Organization (WHO) continue to monitor safety signals across all authorized vaccines, emphasizing that mild to moderate transient reactions are common and typically resolve within a few days.
For individuals with a history of strong inflammatory responses to mRNA vaccines, or those with contraindications such as known hypersensitivity to polyethylene glycol (PEG), protein-based alternatives like Nuvaxovid offer a valuable option. Health authorities in several European countries have updated guidance to reflect this flexibility in vaccine selection, particularly for booster doses.
As of mid-2024, Nuvaxovid remains available in over 30 countries through bilateral agreements and COVAX allocations, though its global uptake has been more limited than mRNA vaccines due to earlier authorization timelines and production scaling challenges. Sanofi has since expanded manufacturing capacity in collaboration with partners to improve accessibility.
Understanding the Vaccine Platforms: How Nuvaxovid and Spikevax Differ
The fundamental difference between Nuvaxovid and Spikevax lies in their underlying technology. Nuvaxovid is a subunit vaccine that contains purified pieces of the SARS-CoV-2 spike protein, formulated as nanoparticles to enhance immune recognition. It relies on the Matrix-M adjuvant, derived from saponins, to stimulate a stronger and more durable immune response. This approach mimics traditional vaccine methods used for influenza and hepatitis B.
Spikevax, utilizes messenger RNA (mRNA) technology. It delivers genetic instructions that instruct host cells to temporarily produce the spike protein, thereby triggering an immune response. While highly effective, this platform can provoke more pronounced innate immune activation, particularly after the second dose, leading to higher rates of transient systemic symptoms.
Clinical trial data from the pivotal Phase III studies showed comparable efficacy between the two vaccines against symptomatic infection caused by ancestral and early variant strains. However, direct comparative trials assessing reactogenicity have been limited, making real-world surveillance data essential for informing tolerability comparisons.
A 2023 study published in The Lancet Infectious Diseases analyzed adverse event reports from national pharmacovigilance systems in Scandinavia and found that recipients of protein-based vaccines reported significantly lower rates of grade 3 fever (temperature ≥39.0°C) and severe myalgia compared to mRNA vaccine recipients after booster doses. The researchers noted that while both platforms maintained strong safety profiles, the difference in reactogenicity could influence patient preference and adherence in repeat vaccination scenarios.
These findings align with pharmacovigilance data from the EMA’s EudraVigilance system, which has consistently shown lower reporting rates of systemic adverse events following Nuvaxovid administration compared to mRNA-based vaccines in adult populations.
Who Might Benefit from Choosing Nuvaxovid?
Certain populations may find Nuvaxovid particularly advantageous due to its tolerability profile. These include individuals who experienced severe or prolonged side effects after mRNA vaccination, those with a history of autoimmune or inflammatory conditions where minimizing immune stimulation is a clinical consideration, and people with known allergies to components of mRNA vaccines such as PEG or polysorbate 80.
Older adults, who may be more susceptible to dehydration or discomfort from high fever, have also been identified in some national guidelines as a group for whom protein-based vaccines could be preferentially considered, especially when mRNA options are contraindicated or poorly tolerated.
Importantly, neither vaccine contains live virus, and both are non-infectious. They do not alter DNA and are cleared from the body within days after eliciting an immune response. Long-term safety data continue to support the use of both platforms, with no evidence of increased risk for serious adverse events such as myocarditis or thrombosis with thrombocytopenia syndrome (TTS) beyond what has been established for mRNA vaccines in younger males.
Healthcare providers are encouraged to discuss vaccine options with patients based on individual medical history, prior vaccine experiences, and accessibility. Shared decision-making remains a cornerstone of modern immunization practice, particularly as the Covid-19 vaccine landscape evolves toward periodic booster recommendations aligned with circulating variants.
Global Availability and Future Outlook
Despite its favorable tolerability, Nuvaxovid has faced challenges in achieving widespread global distribution. Initial authorization by the EMA occurred in December 2021, several months after mRNA vaccines, which limited its early adoption during peak demand periods. Production constraints and supply chain dependencies further delayed rollout in low- and middle-income countries.
However, recent investments by Sanofi in expanding fill-finish capacity in Europe and technology transfer agreements with manufacturers in Asia and Africa aim to increase annual output to over 100 million doses by 2025. These efforts are supported by funding from the European Union’s HERA incubator and partnerships with Gavi, the Vaccine Alliance.
As the SARS-CoV-2 virus continues to evolve, vaccine manufacturers are updating formulations to target dominant variants. Sanofi has announced that a monovalent XBB.1.5-adapted version of Nuvaxovid completed clinical trials in early 2024 and is under regulatory review in the EU and Switzerland. If authorized, this updated formulation could enhance both immune match and public confidence in protein-based options.
Meanwhile, Moderna continues to refine its mRNA platform, with bivalent and variant-specific boosters already in widespread use. The company is also investigating next-generation self-amplifying RNA and pan-coronavirus candidates, though these remain in preclinical or early clinical stages.
For the public, the availability of multiple vaccine platforms with differing characteristics represents a significant advancement in personalized preventive medicine. Rather than a one-size-fits-all approach, individuals can now consider factors such as tolerability, dosing schedule, and prior vaccine history when making informed choices—supported by transparent, continuously updated safety data.
As health authorities prepare for potential seasonal vaccination campaigns in the fall of 2024, updated recommendations from the WHO’s Strategic Advisory Group of Experts (Immunization) are expected in September. These will likely reflect the latest evidence on vaccine performance, immune durability, and platform-specific considerations.
Readers are encouraged to consult official sources such as their national public health agency, the EMA, or the WHO for the most current guidance on Covid-19 vaccination. Staying informed ensures that decisions are based on the best available science, tailored to individual needs and circumstances.
Sanofi’s protein-based Covid-19 vaccine, Nuvaxovid, has demonstrated a more favorable tolerability profile compared to Moderna’s mRNA-based Spikevax (formerly mNEXSPIKE) in recent head-to-head evaluations, according to data reviewed by global health authorities. The findings, which emerged from comparative safety monitoring in multiple countries, contribute to ongoing discussions about vaccine choice, particularly for populations sensitive to reactogenicity or with specific medical histories.
While both vaccines remain authorized and recommended for use in preventing severe Covid-19, real-world evidence suggests that Nuvaxovid may be associated with lower rates of systemic side effects such as fever, fatigue, and myalgia following administration. These observations are particularly relevant in booster campaigns and for individuals who experienced pronounced reactions after prior mRNA doses.
The comparison does not imply differences in efficacy; rather, it highlights variations in how the immune system responds to different vaccine platforms. Nuvaxovid, developed using recombinant nanoparticle technology with Matrix-M adjuvant, presents the SARS-CoV-2 spike protein in a structured format without using genetic material. In contrast, Spikevax delivers mRNA encoding the spike protein, prompting cells to produce the antigen internally.
This mechanistic distinction may underlie the differing tolerability patterns observed in post-authorization studies. Regulatory bodies including the European Medicines Agency (EMA) and the World Health Organization (WHO) continue to monitor safety signals across all authorized vaccines, emphasizing that mild to moderate transient reactions are common and typically resolve within a few days.
For individuals with a history of strong inflammatory responses to mRNA vaccines, or those with contraindications such as known hypersensitivity to polyethylene glycol (PEG), protein-based alternatives like Nuvaxovid offer a valuable option. Health authorities in several European countries have updated guidance to reflect this flexibility in vaccine selection, particularly for booster doses.
As of mid-2024, Nuvaxovid remains available in over 30 countries through bilateral agreements and COVAX allocations, though its global uptake has been more limited than mRNA vaccines due to earlier authorization timelines and production scaling challenges. Sanofi has since expanded manufacturing capacity in collaboration with partners to improve accessibility.
Understanding the Vaccine Platforms: How Nuvaxovid and Spikevax Differ
The fundamental difference between Nuvaxovid and Spikevax lies in their underlying technology. Nuvaxovid is a subunit vaccine that contains purified pieces of the SARS-CoV-2 spike protein, formulated as nanoparticles to enhance immune recognition. It relies on the Matrix-M adjuvant, derived from saponins, to stimulate a stronger and more durable immune response. This approach mimics traditional vaccine methods used for influenza and hepatitis B.
Spikevax, utilizes messenger RNA (mRNA) technology. It delivers genetic instructions that instruct host cells to temporarily produce the spike protein, thereby triggering an immune response. While highly effective, this platform can provoke more pronounced innate immune activation, particularly after the second dose, leading to higher rates of transient systemic symptoms.
Clinical trial data from the pivotal Phase III studies showed comparable efficacy between the two vaccines against symptomatic infection caused by ancestral and early variant strains. However, direct comparative trials assessing reactogenicity have been limited, making real-world surveillance data essential for informing tolerability comparisons.
A 2023 study published in The Lancet Infectious Diseases analyzed adverse event reports from national pharmacovigilance systems in Scandinavia and found that recipients of protein-based vaccines reported significantly lower rates of grade 3 fever (temperature ≥39.0°C) and severe myalgia compared to mRNA vaccine recipients after booster doses. The researchers noted that while both platforms maintained strong safety profiles, the difference in reactogenicity could influence patient preference and adherence in repeat vaccination scenarios.
These findings align with pharmacovigilance data from the EMA’s EudraVigilance system, which has consistently shown lower reporting rates of systemic adverse events following Nuvaxovid administration compared to mRNA-based vaccines in adult populations.
Who Might Benefit from Choosing Nuvaxovid?
Certain populations may find Nuvaxovid particularly advantageous due to its tolerability profile. These include individuals who experienced severe or prolonged side effects after mRNA vaccination, those with a history of autoimmune or inflammatory conditions where minimizing immune stimulation is a clinical consideration, and people with known allergies to components of mRNA vaccines such as PEG or polysorbate 80.
Older adults, who may be more susceptible to dehydration or discomfort from high fever, have also been identified in some national guidelines as a group for whom protein-based vaccines could be preferentially considered, especially when mRNA options are contraindicated or poorly tolerated.
Importantly, neither vaccine contains live virus, and both are non-infectious. They do not alter DNA and are cleared from the body within days after eliciting an immune response. Long-term safety data continue to support the use of both platforms, with no evidence of increased risk for serious adverse events such as myocarditis or thrombosis with thrombocytopenia syndrome (TTS) beyond what has been established for mRNA vaccines in younger males.
Healthcare providers are encouraged to discuss vaccine options with patients based on individual medical history, prior vaccine experiences, and accessibility. Shared decision-making remains a cornerstone of modern immunization practice, particularly as the Covid-19 vaccine landscape evolves toward periodic booster recommendations aligned with circulating variants.
Global Availability and Future Outlook
Despite its favorable tolerability, Nuvaxovid has faced challenges in achieving widespread global distribution. Initial authorization by the EMA occurred in December 2021, several months after mRNA vaccines, which limited its early adoption during peak demand periods. Production constraints and supply chain dependencies further delayed rollout in low- and middle-income countries.
However, recent investments by Sanofi in expanding fill-finish capacity in Europe and technology transfer agreements with manufacturers in Asia and Africa aim to increase annual output to over 100 million doses by 2025. These efforts are supported by funding from the European Union’s HERA incubator and partnerships with Gavi, the Vaccine Alliance.
As the SARS-CoV-2 virus continues to evolve, vaccine manufacturers are updating formulations to target dominant variants. Sanofi has announced that a monovalent XBB.1.5-adapted version of Nuvaxovid completed clinical trials in early 2024 and is under regulatory review in the EU and Switzerland. If authorized, this updated formulation could enhance both immune match and public confidence in protein-based options.
Meanwhile, Moderna continues to refine its mRNA platform, with bivalent and variant-specific boosters already in widespread use. The company is also investigating next-generation self-amplifying RNA and pan-coronavirus candidates, though these remain in preclinical or early clinical stages.
For the public, the availability of multiple vaccine platforms with differing characteristics represents a significant advancement in personalized preventive medicine. Rather than a one-size-fits-all approach, individuals can now consider factors such as tolerability, dosing schedule, and prior vaccine history when making informed choices—supported by transparent, continuously updated safety data.
As health authorities prepare for potential seasonal vaccination campaigns in the fall of 2024, updated recommendations from the WHO’s Strategic Advisory Group of Experts (Immunization) are expected in September. These will likely reflect the latest evidence on vaccine performance, immune durability, and platform-specific considerations.
Readers are encouraged to consult official sources such as their national public health agency, the EMA, or the WHO for the most current guidance on Covid-19 vaccination. Staying informed ensures that decisions are based on the best available science, tailored to individual needs and circumstances.